Galectin Therapeutics Inc. (GALT) by event type
GALT moves most on rating reiterations — a median of +1.24% at 30 minutes across 19 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the GALT overview →
How GALT reacts across 3 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades 1,854 of 2,717 | 10 | -0.14% | 50% | +0.57% |
| Analyst downgrades 267 of 2,603 | 10 | +0.67% | 60% | -2.83% |
| Rating reiterations 30 of 3,522 | 19 | +1.24% | 74% | +1.81% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 1 further class was observed with fewer than 10 measured events and is not published.
That’s how GALT usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst upgrades → · Analyst downgrades → · Rating reiterations → · GALT overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| NeuroOne Medical Technologies Corporation (NMTC) | 310 | -0.19% | 41% |
| SI-BONE, Inc. (SIBN) | 310 | +0.14% | 56% |
| MENLO THERAPEUTICS INC COMMON (MNLO) | 308 | 0.00% | 49% |
| Syros Pharmaceuticals, Inc. (SYRS) | 307 | +0.51% | 55% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.